MedTrace Logo

The CorEvitas Psoriasis (PSO) Registry

NCT02707341 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-02-09

No results posted yet for this study

Summary

The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.

Conditions

Sponsors & Collaborators

  • CorEvitas

    lead NETWORK

Principal Investigators

  • Jeffrey Greenberg, MD, MPH · CorEvitas

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2100-12-31
Completion
2100-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02707341 on ClinicalTrials.gov